I am a board-certified hematologist specializing in the treatment of multiple myeloma and other plasma cell neoplasms. I have a particular research interest in early plasma cell disorders, including monoclonal gammopathy of unknown significance (MGUS) and smoldering myeloma (SMM), and understanding disease biology that may promote transition to frank symptomatic multiple myeloma in some individuals. My colleagues at Memorial Sloan Kettering and I offer a variety of treatment options (on and off clinical trial) for patients with multiple myeloma and high-risk SMM, including access to the latest novel drugs and immune-therapeutic approaches. Recent therapeutic advances have led to improved outcomes for people with multiple myeloma, and I am working on developing methods of monitoring minimal residual disease. By understanding mechanisms of tumor resistance with current available drugs and monitoring techniques, we aim to drive myeloma research forward and develop new strategies of tumor control or eradication.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811